Patents Represented by Attorney, Agent or Law Firm Alan L. Koller
  • Patent number: 8252815
    Abstract: A compound of the formula (I), (II), (III) or (IV) wherein Z, A, B, C, R, R1, R2, Q, and n are as described herein.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: August 28, 2012
    Assignee: Purdue Pharma L.P.
    Inventors: Qun Sun, R. Richard Goehring, Donald Kyle, Zhengming Chen, Sam Victory, John Whitehead
  • Patent number: 7563809
    Abstract: The invention relates to benzothiadiazole compounds of formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1, R2, A, B, C, W, Z and n are defined as set forth in the specification. The compounds of the invention have affinity for the nociceptin receptor. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to modulation of the nociceptin receptor. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: March 1, 2005
    Date of Patent: July 21, 2009
    Assignee: Purdue Pharma, L.P.
    Inventors: R. Richard Goehring, Zhengming Chen, John Whitehead, Parviz Gharagozloo, Sam Victory, Donald Kyle
  • Patent number: 6828440
    Abstract: A compound of the formula (I): wherein Z, A, B, C, R1, R2, X1, X2, Q and n are as disclosed herein.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: December 7, 2004
    Assignee: Euro-Celtique, S.A.
    Inventors: R. Richard Goehring, Sam Vicotry, Donald Kyle
  • Patent number: 6828460
    Abstract: The present invention relates to the use of certain resorcinol derivatives as skin lightening agents.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: December 7, 2004
    Assignee: Pfizer Inc.
    Inventors: Andrew Francis Browning, Eric William Collington, Martin James Procter, Joanna Victoria Geden
  • Patent number: 6372242
    Abstract: The present invention provides a device, preferably a collar or ear tag, capable of the controlled, sustained release of an effective amount of an active ingredient that can protect an animal against arthropod pests, comprising a reservoir containing a novel gel formulation comprising a fatty acid, an organic solvent which is a linear aliphatic ester, a silicone-based fluid, or a combination thereof, and an active ingredient that can protect the animal against one or more arthropod pests.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: April 16, 2002
    Assignee: Pfizer Inc
    Inventor: Luis Gutierrez
  • Patent number: 6328974
    Abstract: This invention relates to immunogenic compositions capable of potentiality growth hormone activity, comprising an immunologically effective amount of a composite peptide comprising at least two non-contiguous somatotropin epitope amino acid sequences, wherein said composite peptide is substantially free of receptor binding domain sequences; and an immunologically acceptable excipient. The invention further relates to methods of using an immunogenic composition of the invention to potentiate the action of growth hormone in pigs.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: December 11, 2001
    Assignee: Pfizer Inc
    Inventors: Hector Wasunna Alila, Michael Thomas Clark, Elaine Verne Jones, Timothy Joe Miller, Shawn Patrick O'Brien, Ganesh Madhusudan Sathe
  • Patent number: 6280974
    Abstract: The present invention provides polynucleotide molecules encoding portions of the S protein from feline infectious peritonitis virus (FIPV). The present invention further provides polynucleotide molecules encoding the entire S protein or portions thereof from feline enteric coronavirus (FECV). The polynucleotide molecules of the present invention are useful as diagnostic reagents.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: August 28, 2001
    Assignee: Pfizer Inc
    Inventors: Timothy J. Miller, Albert Paul Reed, Sharon R. Klepfer, Nancy E. Pfeiffer, Brian T. Suiter, Elaine V. Jones
  • Patent number: 6270800
    Abstract: A microencapsulated subunit component from bovine herpes virus-1 (BHV-1) is disclosed. Vaccines, kits, and methods for using the same to vaccinate a member of a bovine species are also disclosed.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: August 7, 2001
    Assignee: Pfizer Inc.
    Inventors: Tully J. Speaker, H. Fred Clark, Charlotte A. Moser, Paul A. Offit, Manuel Campos, Patrick J. Frenchick
  • Patent number: 6271268
    Abstract: A method of treating diseases caused by sebaceous gland disorders, in humans and animals, which comprises administering to said humans and animals a composition comprising a sebaceous gland secretion inhibiting amount of an active compound comprising an acyl coA cholesterol acyl transferase (ACAT) inhibitor or prodrug therefor. A composition for use in treating diseases caused by sebaceous gland disorders such as acne in humans and animals which comprises a sebaceous gland secretion inhibiting amount of an acyl coA cholesterol acyl tanferase (ACAT) inhibitor or prodrug therefor and, optionally, a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: August 7, 2001
    Assignee: Pfizer Inc
    Inventor: James T. Mayne
  • Patent number: 6271370
    Abstract: The present invention relates to an improved method for synthesizing nucleosides with a low &agr;:&bgr; anomeric ratio. The method comprises coupling a protected furanosyl halide and an appropriately protected heterocycle in the presence of a nucleophilic polar solvent and a strong base.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: August 7, 2001
    Assignee: Pfizer INC
    Inventor: Robert W. Scott
  • Patent number: 6248579
    Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: June 19, 2001
    Assignee: Pfizer Inc
    Inventors: Kim J. Stutzman-Engwall, Hamish McArthur, Yoshihiro Katoh
  • Patent number: 6232500
    Abstract: This invention relates to a novel improved process for preparation of N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine from 4-(3,4-dichloro-phenyl)-3,4-dihydro-1(2H)-naphthalenone and monomethylamine.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: May 15, 2001
    Assignee: Pfizer Inc
    Inventors: Juan Carlos Colberg, David Michael Pfisterer, Geraldine Patricia Taber
  • Patent number: 6197591
    Abstract: The present invention is directed to compositions and methods for producing avermectins, and is primarily in the field of animal health. The present invention relates to the identification and characterization of two novel genes, herein referred to as the aveR1 and aveR2 genes, that are involved in regulating avermectin polyketide synthase (PKS) expression and avermectin biosynthesis in Streptomyces avermitilis. The present invention is based on the discovery that inactivation of these genes results in an increase in the amount of avermectin produced by S. avermitilis.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: March 6, 2001
    Assignee: Pfizer Inc.
    Inventors: Kim J. Stutzman-Engwall, Brenda S. Price
  • Patent number: 6177458
    Abstract: This invention relates to the isochroman compound of formula (I) and its pharmaceutically acceptable salts, which are useful as an amyloid aggregation inhibitor and for treating Alzheimer's disease. This invention also relates to processes for producing the isochroman compound, which comprises cultivating Penicillium simplicissimum FERM BP-6357 and then isolating the isochroman compound from the fermentation broth. The present invention also relates to a pharmaceutical composition comprising the isochroman compound.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: January 23, 2001
    Assignee: Pfizer Inc
    Inventors: Hideo Hirai, Toshio Ichiba, Hiroko Tonai
  • Patent number: D437407
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: February 6, 2001
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Patent number: D433499
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: November 7, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Patent number: D433500
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: November 7, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Patent number: D433501
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: November 7, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Patent number: D433750
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: November 14, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Patent number: D434135
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: November 21, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows